- Emcure Pharma becomes the first Indian company with exclusive rights to distribute and commercialise Poviztra®, semaglutide injection 4 mg, for weight loss in India
- This partnership is part of Novo Nordisk’s efforts to make its innovative semaglutide mol- ecule accessible to a greater number of people living with overweight and obesity in In- dia
Novo Nordisk India and Emcure Pharma today announced a strategic partnership to launch Poviztra®, semaglutide injection 2.4 mg, in India. The collaboration will strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India.
Wegovy® (semaglutide injection 2.4 mg) was launched in India in June 2025. It is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management and reduction in the risk of major adverse cardiovascular events in individu- als with overweight or obesity.1 In clinical trials, 1 in 3 participants on Wegovy® experienced weight loss of over 20%.2 Poviztra® is a second brand of Wegovy®.
This partnership is part of Novo Nordisk India’s efforts to ensure its innovative treatments reach a greater number of patients in India, broadening access to high-quality, safe, and effective weight management medication. As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviz- tra®, semaglutide injection 2.4 mg, in India.
Commenting on the partnership, Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk said, “Obesity is a serious chronic disease affecting millions of people across India and results in significant unmet medical needs. Recognising the magnitude of the obesity challenge, we launched Wegovy® in India a few months ago. Now, we are happy to join hands with Emcure Pharma to broaden access to high-quality, safe, and effective obesity treatment. This partnership brings together Novo Nordisk’s innovation in GLP-1 therapies and Emcure’s robust marketing and distribution capabilities to improve access to obesity treatment for people living with over- weight or obesity in India.”
Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma said, “We are thrilled to partner with Novo Nordisk India to bring Poviztra® to India and are proud to be the first Indian pharmaceutical company to bring the world’s most widely used and trusted GLP-1- based weight loss molecule to the Indian market. We believe in the potential of semaglutide.
With our strong understanding of the country’s diverse geographical landscape and established marketing capabilities, we are confident about making this molecule available to patients who need it the most.”
Semaglutide injection 2.4 mg (Wegovy®/Poviztra®) has strong clinical data and has been ex- tensively studied across multiple obesity trials in the STEP and SELECT programmes.
Semaglutide as a molecule has been on the market for close to a decade, has 38 million pa- tient years* of exposure and is supported by robust real-world evidence.1-4
*Number of people who have used semaglutide multiplied by time on medicine
About Poviztra® and Wegovy®
Poviztra®/Wegovy® (semaglutide injection 2.4 mg) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) and 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. It is available in a once-weekly pen device in five dose strengths –
0.25 mg, 0.5 mg, 1 mg, 1.7 mg and a maintenance dosing of 2.4 mg. It comes in a state-of-the- art pen device that provides the convenience of simple administration and precise dosing.
About obesity in India
India has nearly 254 million people living with generalised obesity and another 351 million living with abdominal obesity5. Obesity is linked to over 230 health complications including cardiovas- cular disease, fatty liver, knee osteoarthritis, polycystic ovary syndrome, kidney disease and Alz- heimer’s disease. It is also associated with huge personal, social, and economic costs.6 It is often perceived to be the result of poor lifestyle choices and a lack of self-discipline. However, obesity is caused by many different factors, including genetics, biology, psychology, society, and the envi- ronment we live in. As with other chronic conditions, such as type 2 diabetes or asthma, obesity requires long-term management with effective treatment solutions.
About Novo Nordisk India Private Limited
Novo Nordisk India was established in 1994 and is headquartered in Bengaluru, Karnataka. The com- pany serves as the India affiliate of Novo Nordisk A/S – a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic dis- eases such as diabetes, obesity and rare blood and endocrine disorders. We do so by pioneering scien- tific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure
